The FDA also approved an every 4 week dosing regimen across all approved indications for patients who may not maintain a response on extended dosing intervals following successful initial treatment.

In patients naïve to HER2-targeted therapy, the objective response rate was 71% with a median duration of response of 9.2 months.

Darzalex Faspro ® is a subcutaneous formulation that combines daratumumab, a CD38-directed cytolytic antibody, and hyaluronidase, an endoglycosidase that increases permeability of the subcutaneous ...

The Food and Drug Administration (FDA) has granted traditional approval to Imdelltra ® (tarlatamab-dlle) for the treatment of adults with extensive stage small cell lung cancer (ES-SCLC) with disease ...

The Food and Drug Administration (FDA) has approved Koselugo ® (selumetinib) for adults with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas (PN). Previously, ...

HealthDay News — Most countries involved in clinical trials for US Food and Drug Administration approvals do not gain timely physical access to the medicines that they help evaluate, according to a ...

Countries lose measles elimination status when the same strain spreads for 12 months or more. If transmission continues into January (the 1-year mark) the US could lose the designation it has held for ...

HealthDay News — People paying out of pocket for Ozempic or Wegovy may soon see lower costs, as Novo Nordisk rolls out new price discounts for its popular GLP-1 medications. The company announced that ...